11-12-2017 16:29 CET Reporting of transactions with ALK-Abelló A/S' B-shares and associated securities by person closely associated with person discharging managerial responsibly
11-12-2017 10:51 CET REGISTRATION OF CAPITAL INCREASE OF DKK 92,076 AA SHARES AND DKK 920,760 B SHARES BY THE ISSUE OF NEW SHARES COMPLETED
07-12-2017 13:51 CET Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
07-12-2017 08:01 CET PRICING AND FURTHER DETAILS ON THE OFFERING OF NEW SHARES IN ALK-ABELLÓ A/S
06-12-2017 17:03 CET ALK-ABELLÓ A/S TO ISSUE UP TO 92,076 AA SHARES AND UP TO 920,760 B SHARES IN A PRIVATE PLACEMENT
04-12-2017 07:30 CET ALK launches ambitious, transformational growth strategy
30-11-2017 12:27 CET ALK secures pricing and reimbursement for ACARIZAX® in France
29-11-2017 08:26 CET Management change at ALK
28-11-2017 12:50 CET ALK to launch updated corporate strategy on 4 December
10-11-2017 07:30 CET Nine-month interim report (Q3) 2017
03-11-2017 09:26 CET ALK appoints Søren Jelert as new Chief Financial Officer
03-11-2017 08:23 CET Release date of nine-month interim report (Q3) 2017 and audio cast
12-10-2017 22:43 CET Notification of ownership in ALK
27-09-2017 09:00 CET ALK’s partner, Torii, gains approval for Japanese cedar SLIT-tablet in Japan
21-09-2017 19:39 CET ALK acts on French injunction by accelerating investments in its quality system at the French manufacturing facility
14-09-2017 13:15 CET Successful Phase III trial for ALK’s tree allergy SLIT-tablet
04-09-2017 17:19 CET Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
21-08-2017 18:59 CET ALK to accelerate launches of ODACTRA™ in the USA / ACARIZAX® in Canada
16-08-2017 07:45 CET Six-month interim report (Q2) 2017
08-08-2017 15:39 CET Release date of six-month interim report (Q2) 2017 and audio cast